期刊
CANCER DISCOVERY
卷 3, 期 1, 页码 52-67出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-12-0408
关键词
-
类别
资金
- Anonymous Foundation
- Harry J. Lloyd Charitable Trust
- USPHS [R01CA45708, T32GM07223]
- Yale SPORE in Skin Cancer
- National Cancer Institute [P50 CA121974]
- NATIONAL CANCER INSTITUTE [P50CA121974, R01CA045708] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007223] Funding Source: NIH RePORTER
Resistance and partial responses to targeted monotherapy are major obstacles in cancer treatment. Systematic approaches to identify efficacious drug combinations for cancer are not well established, especially in the context of genotype. To address this, we have tested pairwise combinations of an array of small-molecule inhibitors on early-passage melanoma cultures using combinatorial drug screening. Results reveal several inhibitor combinations effective for melanomas with activating RAS or BRAF mutations, including mutant BRAF melanomas with intrinsic or acquired resistance to vemurafenib. Inhibition of both EGF receptor and AKT sensitized treatment-resistant BRAF mutant melanoma cultures to vemurafenib. Melanomas with RAS mutations were more resistant to combination therapies relative to BRAF mutants, but were sensitive to combinations of statins and cyclin-dependent kinase inhibitors in vitro and in vivo. These results show the use of combinatorial drug screening for discovering unique treatment regimens that overcome resistance phenotypes of mutant BRAF- and RAS-driven melanomas.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据